PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal ...
PLEASANTON, Calif., Aug. 29, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has shipped more than 100 Xenium Analyzer ...
On 4 February 2026, PharosAI announced it would use 10x Genomics’ Xenium spatial platform to convert archived NHS cancer ...
After growing its Xenium In Situ single-cell spatial imaging platform into its third successful technology family last year, 10x Genomics has no plans for launching a fourth platform in 2024—but will ...
Xenium In Situ demonstrates higher transcript counts per gene in new comparison study of three spatial imaging platforms PLEASANTON, Calif., Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (TXG) ...
Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue types PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (TXG) (Nasdaq: TXG), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results